Teva Drug-Label Case Spurs Fresh Litigation as Judges Weigh Redo

Generic drugmakers trying to market copycat medicines with limited-use labels are seeing lawsuits begin to mount after a ruling against Teva Pharmaceutical Industries Ltd. cast the routine practice into doubt.

At least five lawsuits filed since last October challenge the use of “skinny labels,” which allow generic producers to evade patent infringement by selling their own versions of branded drugs for limited purposes. Attorneys say more are on the way unless the Federal Circuit reverses or limits the scope a decision critics argue could hinder access to low-cost drugs.

These lawsuits are emblematic of “the biggest danger” imposed on the ...